Drug Type Radionuclide Drug Conjugates (RDC), Monoclonal antibody, Therapeutic radiopharmaceuticals |
Synonyms 225Ac-DOTA hTAB004 |
Target |
Mechanism MUC1 inhibitors(Mucin-1 inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
MUC1 positive Solid Tumors | Preclinical | US | 06 Jun 2024 | |
Triple Negative Breast Cancer | Preclinical | US | 06 Jun 2024 |